OpenAI just bought a media company to control its narrative. Anthropic just bought a drug discovery startup to control the future of healthcare. Tell me which bet ages better.

Anthropic has acquired Coefficient Bio, a stealth biotech AI startup founded barely eight months ago, in an all-stock deal worth just over $400 million. The company had no public product, no disclosed revenue, and fewer than 10 employees. What it did have: a founding team of former Genentech computational biology researchers with rare credentials in AI-driven drug discovery.

Co-founders Samuel Stanton and Nathan C. Frey both came from Prescient Design, Genentech's computational drug discovery unit. Frey alone has published over 20 papers in journals including Science Advances and Nature Machine Intelligence, and won an ICLR Outstanding Paper Award in 2024 for generative modelling work on drug candidate discovery. This is not a typical acqui-hire. This is Anthropic buying an entire research lineage.

The Math That Matters

Dimension, the VC firm that held roughly half of Coefficient Bio, is now reporting a 38,513 percent internal rate of return on the investment. That number says less about Coefficient Bio's commercial viability than about the insane speed at which AI valuations are repricing early-stage science bets. Against Anthropic's $380 billion post-money valuation from its $30 billion Series G, this acquisition represents roughly 0.1 percent dilution. A rounding error for Anthropic. A life-changing exit for the founders.

The Coefficient Bio team will join Anthropic's Health Care Life Sciences group, led by Eric Kauderer-Abrams, who was hired with an explicit mandate to make Claude the dominant AI model in biology. "We want a meaningful percentage of all of the life science work in the world to run on Claude, in the same way that happens today with coding," Kauderer-Abrams told CNBC when Anthropic launched Claude for Life Sciences in October 2025.

The Strategic Divergence You Should Be Watching

Here is what makes this fascinating. The three biggest AI labs are placing radically different bets on what comes next. OpenAI bought TBPN, a media company, to control narrative and distribution ahead of its IPO. Google is open-sourcing Gemma 4 to win developer mindshare. And Anthropic just spent $400 million on the thesis that general-purpose AI can revolutionize how we discover drugs.

One of these companies is building infrastructure for a world where AI cures diseases. The other is building infrastructure for a world where AI generates better PR. The market will eventually pick a winner, and I know which one I would bet on.

Coefficient Bio's stated ambition was nothing modest: artificial superintelligence for science. Their platform enabled AI to draft drug R&D plans, manage clinical regulatory strategies, and identify new drug candidates. That capability now belongs to Claude.

What Happens Next

Anthropic is positioning Claude as the default operating system for biology. Between this acquisition, the Claude for Life Sciences platform (which integrates with Benchling, PubMed, and 10x Genomics), and the AnthroPAC political operation it just launched, Dario Amodei is clearly playing a longer game than anyone else in the room. While OpenAI optimizes for IPO optics and Google optimizes for open-source goodwill, Anthropic is quietly building the infrastructure that could make AI indispensable to the most regulated, highest-stakes industry on the planet.

Healthcare AI is a $187 billion market by 2030. Anthropic just bought its ticket. First reported by The Information.